Back to top
more

Eton Pharmaceuticals (ETON)

(Delayed Data from NSDQ)

$5.94 USD

5.94
56,372

+0.03 (0.51%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $5.93 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 48.28% and -54.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Teladoc's (TDOC) Q4 performance is likely to have benefited from increased membership and visits.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

by Zacks Equity Research

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

by Zacks Equity Research

Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

Regeneron Ebola Treatment Shows Promise, Study Stopped Early

by Zacks Equity Research

Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.

Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

by Zacks Equity Research

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.

Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.